AMGN · 8-K · 20261103PR000153

Guidance and Outlook

AMGEN INC · 2026-11-03 · Importance 60 · Surprise 24 · In source text

Amgen’s 2026 GAAP diluted EPS guidance is $18.34–$19.28, while non-GAAP diluted EPS guidance is $22.90–$23.70. The company’s 2026 GAAP tax-rate guidance is 14.5%–16.0%, compared with non-GAAP tax-rate guidance of 15.0%–16.5%. The non-GAAP guidance adjustments include acquisition-related expenses, net gains from equity investments, and other items; the filing says GAAP EPS guidance excludes adjustments triggered by subsequent events such as acquisitions, impairments, litigation, and changes in fair value.

Key facts

• Amgen expected full-year 2026 total revenues of $38.9 billion to $39.7 billion. source
• Amgen expected full-year 2026 GAAP EPS of $18.34 to $19.28 and a GAAP tax rate of 14.5% to 16.0%. source
• Amgen expected full-year 2026 non-GAAP EPS of $22.90 to $23.70 and a non-GAAP tax rate of 15.0% to 16.5%. source
• For the year ending December 31, 2026, Amgen's GAAP diluted EPS guidance is $18.34–$19.28 and non-GAAP diluted EPS guidance is $22.90–$23.70. source
• The known adjustments to 2026 non-GAAP diluted EPS guidance are presented net of related tax impact of approximately $0.70 per share. source
• For the year ending December 31, 2026, Amgen's GAAP tax rate guidance is 14.5%–16.0% and non-GAAP tax rate guidance is 15.0%–16.5%. source
• Amgen's GAAP diluted EPS guidance excludes GAAP adjustments triggered by subsequent events such as acquisitions, asset impairments, litigation, changes in fair value of contingent consideration obligations, and changes in fair value of equity investments. source

Impact estimates